The identification of oncogenic activation of tyrosine kinases in some advanced NSCLC tumors, most notably mutations in the EGFR, ALK or ROS1 gene, has led to a paradigm shift and the development of specific molecular treatments for patients (66). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.